PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells
- 6 January 2022
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (5) , 999-1009
Abstract
Purpose Cushing's disease is associated with significant morbidity; thus, additional tumor-directed drugs with the potential to exert antineoplastic effects on corticotroph adenoma cells are desired. The phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) pathway, which plays regulatory role in cell survival and proliferation, is activated in pituitary adenomas. The present study evaluated the effects of BKM120 (Buparlisib), an oral PI3K inhibitor, on cell viability, apoptosis, cell cycle phase distribution, and ACTH production in mouse corticotroph tumor cells. Methods AtT-20/D16v-F2 mouse pituitary corticotroph tumor cells were treated with increasing concentrations of BKM120 or vehicle. Cell viability was measured using an MTS-based assay. Apoptosis was evaluated by Annexin V staining. Cell cycle analysis was performed by propidium iodide DNA staining and flow cytometry. Gene expression of cell cycle regulators (Cdkn1b, Ccnd1, Ccne1, Cdk2, Cdk4, Myc, and Rb1) was assessed by qPCR. Protein expression of p27, total and phosphorylated Akt was assessed by Western blot. ACTH levels were measured in the culture supernatants by chemiluminescent immunometric assay. Results Treatment with BKM120 decreased AtT-20/D16v-F2 cell viability, induced a G0/G1 cell cycle arrest, reduced the phosphorylation of Akt at Serine 473, and increased p27 expression. Furthermore, BKM120 treatment diminished ACTH levels in the cell culture supernatants. Conclusion In vitro inhibition of PI3K/AKT pathway by BKM120 resulted in anti-proliferative effects on corticotroph tumor cells, decreasing cell viability and ACTH production. These encouraging findings shape the path for further experiments with the inhibition of PI3K/AKT pathway in Cushing’s disease.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/03989-6)
This publication has 42 references indexed in Scilit:
- Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of ConcentrationsMolecular Cancer Therapeutics, 2012
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase InhibitorMolecular Cancer Therapeutics, 2012
- EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomasJournal of Clinical Investigation, 2011
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating CancerACS Medicinal Chemistry Letters, 2011
- Platelet-derived Growth Factor (PDGF) and PDGF Receptor Expression and Function in Folliculostellate Pituitary CellsExperimental and Clinical Endocrinology & Diabetes, 2009
- Frequent mutations and amplifications of the PIK3CA gene in pituitary tumorsEndocrine-Related Cancer, 2009
- Activation of Phosphatidylinositol 3-Kinase Signaling Promotes Aberrant Pituitary Growth in a Mouse Model of Thyroid-Stimulating Hormone-Secreting Pituitary TumorsEndocrinology, 2008
- Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 ExpressionCancer Research, 2006
- Enhanced protein kinase B/Akt signalling in pituitary tumoursEndocrine-Related Cancer, 2005
- The Luteinizing Hormone-releasing Hormone Inhibits the Anti-apoptotic Activity of Insulin-like Growth Factor-1 in Pituitary αT3 Cells by Protein Kinase Cα-mediated Negative Regulation of AktJournal of Biological Chemistry, 2004